Supriya Lifescience Limited IPO Message Board (Page 15)

SUPRIYA LIFESCIENCE (SLS) IPO
Positives -
1) API sector is going to benefit exponentially because of china + 1 policy. SLS is well placed to take advantage of this opportunity.
2) Based on FY21, EPS = 15.4, BV/share = 33, P/BV = 8.2, PE = 17.8 which look very reasonable when compared to its competitors - Divis Lab PE = 56.90 and Aarti Drugs PE = 24.30
3) Revenue growth = FY20 : 12%, FY21 : 24%
EBIDTA margins = FY19 : 23.30%, FY20 : 31.60%, FY21 : 43.4%, H1FY22 : 41.60%
PAT margins = FY19 : 14.20%, FY20 : 23.60%, FY21 : 32.10%, H1FY22 : 29.30%
EV/EBIDTA = FY21 : 13.30, H1FY22 : 11.80
PE RATIO = FY21 : 17.80, H1FY22 : 16.70
DEBT/EQUITY = 0.5 which is very comfortable and proceeds from the issue will
be used to repay the debt.
Excellent growth overall with improving margins. It''s EBITDA margins and ROE is the best in the industry and it''s PE and EV/EBITDA is among the lowest.
4) R&D spending is increasing gradually - from 8.61 million rupees in FY19 to 15.33 million rupees in FY21. H1FY22 spending is already 14.43 million rupees.

Negatives -
1) Dependent on china for approximately 32% of its total raw material cost.
2) Proceedings against the company - Criminal : 2 cases, Regulatory : 2 cases with approx amount 35.36 million rupees, Tax : 1 case with approx amount 6.55 million rupees.
3) Anchor list is pretty boring and there are no prominent FIIs.

Risks -
1) Export sales as a % of total revenue : 73-78%, any quality issues with it''s product and any withdrawal of certification from Drug approval agencies of respective countries may adversely affect its sales.
2) Contingent liabilities - 16.16 million rupees


Considering the positives, the negatives and risks look very manageable. Markets usually reward these kind of companies that have superior performance in every sector.
Subscription figures are expected to be astronomical as this is one of the best IPOs in December which has left a lot of scope for high listing gains for investors.
Apply with FF.

"Blessing in disguise". Good to remove SH quota, otherwise in more losses. No doubt, they are not friendly. Purchased for SH quo GPL, a loss now. Already in losses in GLS.

@pkraj Same with me. In loss atm in Glenmark parent company but will continue to hold for long term as the amount of investment is very low.

Is me retailer''s ko only 10% ho Q Rapha hy
Company last 3 years me to profit hi dekhata hy??????? Please and expert replay???

@Noorul ji,

If all conditions of regulation 6(1) of SEBI ICDR are met, then the Company HAS TO offer "not less than thirty five percent to retail individual investor".

I am quoting from the SEBI regulation. In this case, they are not meeting one criteria of regulation 6(1), hence 10% retail.

In plain language, You mean to say that company does not have ENOUGH ready cash to meet the desired criteria to qualify for having 35% retail quota, but cash equivalent such as trade receivables, tax benefits receivables and govt. incentives receivable (yet to receive)., is it so?, just want to understand by academic point of view and no reason else.

**Supriya Lifescience ipo is no brainer for me.

Can anyone please share anchor link...

@arvind- It''s shared on this forum only where you have DRHP, RHP links...
link- https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20211215-64&attachedId=972650e9-3a7c-4945-9bc8-ecb076e0dacc

Thanks!

Gmp - 250-260

LATEST GMP👇
Medplus 255/260
data 465/75
Metro 13-15
MapMyIndia 935/945
Shriram Prop 16.5/17.5
Rate Gain 18/22
Supriya 295-305

Only 10% shares are reserved for retail investors, so chances of allotment for retail investors is very thin.

Impressive Anchor list… ‘Listing pe double’ candidate!!! Apply if you have funds for bumper listing gains…

CMS Info Systems IPO opens on December 21, to raise Rs 1,100 crore
CMS Info Systems IPO | Half of the offer is reserved for qualified institutional buyers (including anchor investors), 15 percent for non-institutional investors, and the remaining 35 percent for retail investors.

CMS Info Systems

Issue Date : 21 - 23 Dec, 2021
Retail quota : 35%
Face Value : Rs 10

@Rajendraji, please confirm the issue size

Issue size has been Reduced to 1100 Crore.
100% OFS

Amazing Anchor book
Names like Nippon smallcap , Malabar Fund, Abakkus (Sunil Singhania)

I think it would be last IPO for 2021 year .
Or
Anyone will come

@ Amit Sir,

may be one more co. named esds could come in Dec 2021. but final update is awaited in this regard.

Thanks

CMS infosystem expected to be the last IPO of the year

I have to require Last year F.Y. 2021 balance sheet of the subject company for depth information. i am trying to the company website i.e. https://supriyalifescience.com/ but not available. If anyone knows pls share link...

Go to MCA 21 website Pay Rs 100 and download much more including balancesheets

Dear experts Supriya subscribe for listings gain or not???

YES

Dear experts hp adhesive subscribe for listings gain or not???

NO

Is me retailer''s ko only 10% ho Q Rakha hy and expert
expert replay???

Is me retailer''s ko only 10% ho Q Rakha hy and expert
expert replay???

Posting for public benefit:

This IPO has 10% retail despite consistent profitability, is because of a clause that gets triggered very rarely (also seen in latentview):

More than 50% of net tangible assets are held in monetary assets - implying good cash flow generation and large amounts of cash equivalents on books.

Source - SEBI ICDR clause 6(1)a

Thanks! Good to know this.

CMS Infosystems Ltd
Opens : 21st Dec 2021
Closes : 23rd Dec 2021

Can i apply IPO from 5 different PAN account but upi will be same?

Yes you can apply... I do the same and multiple time i got the allotment too. I am using kite (by zerodha) to apply for IPO

S

Priority on the basis of Chances of Allotment and Listing Gain :

1️⃣ Data Patterns IPO
GMP : Rs 450 - Rs 500 Per Share

2️⃣ Supriya Lifescience IPO
GMP : Rs 220 - Rs 225 Per Share

3️⃣ Medplus Health IPO
GMP : Rs 110 - Rs 120 Per Share